Multispecific Binding Agent for PD-L1 and CD137 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies using CD137 and PD-L1 binding agents in combination with PD-1 inhibitors are not sufficient in preventing tumor progression and treating cancer effectively.
Innovation Solution
A binding agent that simultaneously binds to human CD137 and PD-L1, combined with a PD-1 inhibitor, utilizing specific variable region sequences to enhance immune response, is administered to subjects to reduce or prevent tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a binding agent that simultaneously binds to CD137 and PD-L1 is used in combination with a PD-1 inhibitor, then the immune response is significantly amplified and tumor progression is reduced, but the device complexity and manufacturing precision requirements increase due to the need for specific variable region sequences
Solution Approach 1:
The patent combines two binding functions into a single binding agent molecule. The binding agent comprises a first binding region that binds to CD137 and a second binding region that binds to PD-L1, merging the functions of separate CD137 and PD-L1 binding agents into one molecule. This reduces the number of separate components needed while achieving synergistic immune response amplification when combined with PD-1 inhibitors.
Solution Approach 2:
The binding agent performs multiple functions simultaneously: it binds to CD137 to provide agonistic signaling, binds to PD-L1 to block the PD-1/PD-L1 interaction, and can be administered in combination with PD-1 inhibitors. This multi-functionality is achieved through the single binding agent molecule containing both binding regions with specific variable region sequences.
2Reliability
If specific variable region sequences are used to enhance immune response, then the effectiveness against cancer is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent specifies particular variable region sequences for the binding regions to ensure optimal binding affinity and immune response amplification. The first binding region has specific variable region sequences for CD137 binding, and the second binding region has specific variable region sequences for PD-L1 binding. These localized sequence specifications ensure the binding agent performs its dual function effectively while maintaining manufacturability through defined sequence requirements.
Data Source
AI summary
The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.